Abstract
Aims: The purpose of this report is to asses the prognostic factors that could influence management and clinical outcome of malignant fibrous histiocytoma (MFH) of soft tissues. Methods: Between 1990 and 2000, 79 patients diagnosed with localized disease by MFH, seen at Santa Creu i Sant Pau Hospital, have been reviewed. 45 were women and 34 were men. The median age at presentation was 62 years (range: 20–85). The median follow-up was 60 months (range: 1–119). Low grade tumors constituted 8% and the remaining 92% were high grade. Several treatment modalities with or without radiotherapy and/or chemotherapy were associated and assessed. We used Kaplan-Meier method for calculating survival rates and Log-Rank test to assess presumed prognostic factors like sex, age, anatomic side, Enneking stage and associated quimio/radiotherapy. Results: Thigh were the most common location (50%). Isolated local recurrence occurred in 19 patients (24%), isolated meta-static disease without local recurrence in 4 patients (5%), and combined local and metastatic disease occurred in 4 patients (5%). The 2- and 5-year relapse-free survival (RFS) rates were 71% and 67%, respectively.
The 2- and 5-year overall survival (OS) rates were 92% and 86% respectively. We found that only Enneking stage was significant prognostic factor (p< 0.05). The best results in SLE were found in surgery + radiotherapy group but it was not statistically significant (p> 0.05). Conclusions: In our opinion, wide complete surgical resection at the time of primary tumor in combination with local radiotherapy is likely to afford the best chance for RFS and OS. Enneking stage seems to be the most important prognostic factor.
The role of adyuvant chemotherapy remains investigational.
Theses abstracts were prepared by Professor Dr. Frantz Langlais. Correspondence should be addressed to him at EFORT Central Office, Freihofstrasse 22, CH-8700 Küsnacht, Switzerland.
